logo
  

Vivendi Shareholders Approve All Resolutions

French media conglomerate Vivendi (VIV.L,VIVEF.PK) said that its shareholders approved all resolutions submitted to the vote, including those requiring a two-thirds majority, among which the resolution authorizing the Management Board to make a public share buyback offer for up to 50% of the share capital.

Vivendi's Annual General Shareholders' Meeting was held Tuesday under the chairmanship of Yannick Bolloré with a quorum of 68.99% of shareholders.

The shareholders approved the distribution of 60% of Universal Music Group shares with a record level of 99.9% positive votes. The listing of the company on Euronext Amsterdam could take place on September 21, 2021.

The shareholders approved the payment of an ordinary dividend of 0.60 euros per share with respect to fiscal year 2020. The dividend will be paid as from June 25, 2021, with an ex-dividend date of June 23, 2021.

On Sunday, Hedge-fund billionaire William Ackman's Pershing Square Tontine Holdings Ltd. (PSTH) agreed to acquire 10% of Universal Music Group from French media conglomerate Vivendi for about $4 billion

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT